Alaunos Therapeutics, Inc. Net Change in Cash
Alaunos Therapeutics, Inc. (TCRT) reported Net Change in Cash of -$1.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$1.03M.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$772.00K.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$1.92M.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$15.56M.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $294.00K.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$4.97M.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$46.93M.
- Alaunos Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$23.06M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.26M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$1.03M 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $294.00K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $847.00K 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $1.79M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$772.00K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | -$4.97M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | -$4.38M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$3.60M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$1.92M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$46.93M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$41.05M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$34.68M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$15.56M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$23.06M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$24.31M 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | -$16.04M 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | -$7.80M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | -$39.02M 10-K · filed 2023-03-07 | |||
| 2021-09-30 | -$23.34M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$38.32M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | -$15.01M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $35.33M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $55.73M 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $73.78M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $91.26M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $18.01M 10-K · filed 2021-03-01 | |||
| 2019-09-30 | $26.69M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$18.17M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$10.24M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$9.61M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$39.22M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | -$30.54M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | -$19.84M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | -$10.11M 10-K · filed 2020-03-02 | |||
| 2017-09-30 | $3.35M 10-Q · filed 2018-11-09 | |||
| 2016-12-31 | -$59.66M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |